Cargando…
Approach to the Patient With Prader–Willi Syndrome
Prader–Willi syndrome (PWS) is a rare, multisystemic, genetic disorder involving the hypothalamus. It is caused by loss of expression of paternally inherited genes in chromosome 15 q11-13 region. The estimated incidence is around 1 in 20.000 births. PWS is characterized by a complex lifelong traject...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635059/ https://www.ncbi.nlm.nih.gov/pubmed/35150573 http://dx.doi.org/10.1210/clinem/dgac082 |
_version_ | 1784824625326194688 |
---|---|
author | Höybye, Charlotte Tauber, Maithé |
author_facet | Höybye, Charlotte Tauber, Maithé |
author_sort | Höybye, Charlotte |
collection | PubMed |
description | Prader–Willi syndrome (PWS) is a rare, multisystemic, genetic disorder involving the hypothalamus. It is caused by loss of expression of paternally inherited genes in chromosome 15 q11-13 region. The estimated incidence is around 1 in 20.000 births. PWS is characterized by a complex lifelong trajectory involving neurodevelopmental, nutritional, endocrine, metabolic, and behavioral changes. The major symptoms are hypotonia, short stature, hypogonadism, and eating disorders ranging from anorexia in infancy to hyperphagia, a deficit of satiety, and a high risk of severe obesity. The patients display intellectual disability comprising cognitive deficit, delayed motor and language development, learning deficits, impaired social skills, and emotional regulation. Behavioral features including temper outbursts, anxiety, obsessive–compulsive symptoms and rigidity are common and become more apparent with increasing age. Almost all have hypogonadism and growth hormone deficiency. Central adrenal insufficiency is rare whereas central hypothyroidism occurs in up to 30% of children with PWS. The prevalence of obesity increases with age from almost none in early childhood to more than 90% in adulthood. Up to 25% of adults with obesity have type 2 diabetes. Obesity and its complications are the major causes of comorbidity and mortality in PWS. As there is no specific treatment, care consists of comprehensive management of feeding disorders, a restricted, controlled diet, regular exercise, hormone substitution, and screening and treatment of comorbidities. Here we present the course of PWS from birth to adulthood in 2 patients and discuss their symptoms in relation to the literature. |
format | Online Article Text |
id | pubmed-9635059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96350592022-11-07 Approach to the Patient With Prader–Willi Syndrome Höybye, Charlotte Tauber, Maithé J Clin Endocrinol Metab Approach to the Patient Prader–Willi syndrome (PWS) is a rare, multisystemic, genetic disorder involving the hypothalamus. It is caused by loss of expression of paternally inherited genes in chromosome 15 q11-13 region. The estimated incidence is around 1 in 20.000 births. PWS is characterized by a complex lifelong trajectory involving neurodevelopmental, nutritional, endocrine, metabolic, and behavioral changes. The major symptoms are hypotonia, short stature, hypogonadism, and eating disorders ranging from anorexia in infancy to hyperphagia, a deficit of satiety, and a high risk of severe obesity. The patients display intellectual disability comprising cognitive deficit, delayed motor and language development, learning deficits, impaired social skills, and emotional regulation. Behavioral features including temper outbursts, anxiety, obsessive–compulsive symptoms and rigidity are common and become more apparent with increasing age. Almost all have hypogonadism and growth hormone deficiency. Central adrenal insufficiency is rare whereas central hypothyroidism occurs in up to 30% of children with PWS. The prevalence of obesity increases with age from almost none in early childhood to more than 90% in adulthood. Up to 25% of adults with obesity have type 2 diabetes. Obesity and its complications are the major causes of comorbidity and mortality in PWS. As there is no specific treatment, care consists of comprehensive management of feeding disorders, a restricted, controlled diet, regular exercise, hormone substitution, and screening and treatment of comorbidities. Here we present the course of PWS from birth to adulthood in 2 patients and discuss their symptoms in relation to the literature. Oxford University Press 2022-02-12 /pmc/articles/PMC9635059/ /pubmed/35150573 http://dx.doi.org/10.1210/clinem/dgac082 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Approach to the Patient Höybye, Charlotte Tauber, Maithé Approach to the Patient With Prader–Willi Syndrome |
title | Approach to the Patient With Prader–Willi Syndrome |
title_full | Approach to the Patient With Prader–Willi Syndrome |
title_fullStr | Approach to the Patient With Prader–Willi Syndrome |
title_full_unstemmed | Approach to the Patient With Prader–Willi Syndrome |
title_short | Approach to the Patient With Prader–Willi Syndrome |
title_sort | approach to the patient with prader–willi syndrome |
topic | Approach to the Patient |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635059/ https://www.ncbi.nlm.nih.gov/pubmed/35150573 http://dx.doi.org/10.1210/clinem/dgac082 |
work_keys_str_mv | AT hoybyecharlotte approachtothepatientwithpraderwillisyndrome AT taubermaithe approachtothepatientwithpraderwillisyndrome |